Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults

Comparison of the immunogenicity and safety of polysaccharide and protein-conjugated pneumococcal vaccines among the elderly aged 80 years or older in Japan: An open-labeled randomized study

(2015) Ho Namkoong et al.   VACCINE

Etiology and Factors Contributing to the Severity and Mortality of Community-acquired Pneumonia

(2014) Takashi Ishiguro et al.   INTERNAL MEDICINE

Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine–naïve adults 60–64 years of age

(2014) Richard N. Greenberg et al.   VACCINE

Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy Japanese adults aged ≥50 years

(2014) Masanari Shiramoto et al.   Human Vaccines & Immunotherapeutics

Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults

(2014) Christine Juergens et al.   Human Vaccines & Immunotherapeutics

Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older

(2013) Lisa A. Jackson et al.   VACCINE

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

(2013) Lisa A. Jackson et al.   VACCINE

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults

(2013) Lisa A. Jackson et al.   VACCINE

Sustained functional serotype-specific antibody after primary and secondary vaccinations with a pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease

(2013) Nobuharu Ohshima et al.   VACCINE

Demand for pneumococcal vaccination under subsidy program for the elderly in Japan

(2012) Masahide Kondo et al.   BMC HEALTH SERVICES RESEARCH

Pneumococcal Conjugate and Plain Polysaccharide Vaccines Have Divergent Effects on Antigen-Specific B Cells

(2012) Elizabeth A. Clutterbuck et al.   JOURNAL OF INFECTIOUS DISEASES

Pneumococcal polysaccharide 23-valent vaccine: Long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adults

(2012) John D. Grabenstein et al.   VACCINE

Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales

(2012) Nick J. Andrews et al.   VACCINE

Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults

(2011) Daniel M. Musher et al.   Human vaccines & immunotherapeutics

The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A

(2011) David Cooper et al.   VACCINE

Pneumococcal Vaccination and Revaccination in the Elderly Population

(2010) Kristin L. Nichol   JOURNAL OF INFECTIOUS DISEASES

Revaccination with a 23‐Valent Pneumococcal Polysaccharide Vaccine Induces Elevated and Persistent Functional Antibody Responses in Adults Aged ⩾65 Years

(2010) Susan B. Manoff et al.   JOURNAL OF INFECTIOUS DISEASES

Serotype and antibiotic resistance of isolates from patients with invasive pneumococcal disease in Japan

(2009) N. CHIBA et al.   EPIDEMIOLOGY AND INFECTION